Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 28, 2023, covers events occurring at Trevi Therapeutics, Inc.'s 2023 Annual Meeting of Stockholders. The Company is a Delaware corporation with its principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "TRVI."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions rather than financial performance data.
Material Changes and Corporate Actions
- Amendment to Certificate of Incorporation: Stockholders approved an amendment to update the director exculpation provision to include certain senior corporate officers. The amendment became effective upon filing with the Delaware Secretary of State on June 28, 2023.
- Board of Directors Election: Two Class I directors were elected for terms expiring at the 2026 annual meeting:
- James Cassella, Ph.D.: Received 31,870,641 votes "For," 5,581,669 "Withheld," and 7,125,050 Broker Non-Votes.
- Michael Heffernan: Received 37,302,433 votes "For," 149,877 "Withheld," and 7,125,050 Broker Non-Votes.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 44,552,048 "For," 8,732 "Against," and 16,580 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the results of the stockholder vote and the effective date of the charter amendment.
Key Facts for Investor Verification
- Verify the full text of the Certificate of Amendment (Exhibit 3.1) to understand the specific scope of the expanded exculpation provision for senior officers.
- Confirm the total number of shares outstanding and the percentage of votes cast "For" versus "Withheld" for the director nominees to assess stockholder sentiment.
- Review the Company's subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent from this 8-K.